PARKINSON'S DISEASE NEWS
Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail firstname.lastname@example.org.
LOW RESOLUTION VERSION : There is a low resolution version of this web page FOR THOSE PEOPLE THAT EITHER : use 800x600 resolution on their monitors, OR have eyesight difficulties, or have slow INTERNET SPEEDS GO TO LOW RESOLUTION VERSION
17th November 2013 - New research
FUNGAL CAUSE OF PARKINSON'S DISEASE
Proceedings of the National Academy of Sciences USA  Nov 11 [Epub
ahead of print] (A.A.Inamdar, M.M.Hossain, A.I.Bernstein, G.W.Miller,
it has not yet conclusively been proven to have caused Parkinson's Disease
in humans, further
experiments in human cells revealed that Octenol interfered with two
genes involved in the creation of dopamine - the human plasma membrane
dopamine transporter (DAT) and the human VMAT ortholog (VMAT2). This
demonstrates that 1-octen-3-ol exerts toxicity via disruption of dopamine
homeostasis and so may represent a naturally occurring cause of Parkinsonism.
Octenol can often be inhaled by humans after being produced in damp, mouldy
or water damaged buildings. In order to refer to this article on its own
16th November 2013- New book
PARKINSON'S DISEASE : A COMPLETE GUIDE FOR PATIENTS AND FAMILIES
William J.Weiner, Lisa M.Shulman, Anthony E.Lang
Publisher's description : Patients and families have long relied on this book for reliable advice about medical, emotional, and physical issues. Bringing this guide up to date, three expert neurologists describe : New understandings gained by five years of additional research on Parkinson’s disease, a new focus on exercise, imaging techniques such as SPECT Scan and DATScan that are aiding in diagnosis, new findings about the genetics, promising uses of new technologies such as tablet devices for people who have trouble communicating, information about impulse control disorders caused by some drugs used to address the symptoms of the disease, A complete update on treatments. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articless are added to Parkinson's Disease News, please merelyy e-mail email@example.com with the message "subscribe". No form of identity is required. E-mail addresses are not used for any other purpose.
12th November 2013 - New research
NEW DRUG FOR PARKINSON'S DISEASE PSYCHOSIS
Lancet  Oct 31 [Epub ahead of print] (J.Cummings, S.Isaacson, R.Mills,
H.Williams, K.Chi-Burris, A.Corbett, R.Dhall, C.Ballard)
They took 40mg pimavanserin per day. The primary measure was the antipsychotic benefit using the Parkinson's disease-adapted scale for assessment of positive symptoms (SAPS-PD). According to the Parkinson's disease-adapted scale for assessment of positive symptoms (SAPS-PD) those people taking pimavanserin reduced their score by 5.79 compared with a reduction of 2.73 by those taking a placebo. Over 10% of the patients discontinued because of an adverse event. However, in previous clinical trials there was either no effect Complete abstract, or it was beneficial for some but not all measures of psychosis Complete abstract. In order to refer to this article on its own click here.
10th November 2013 - New research
THE PREVALENCE OF HEADACHES IN PARKINSON'S DISEASE
Neurological Sciences  Nov 7 [Epub ahead of print] Complete abstract
Researchers assessed the prevalence of headache in people with Parkinson's Disease and the association between the side of Parkinon's Disease symptom onset and the side of their headache. Headaches were found to occur significantly less in people with Parkinson's Disease, 40% of whom had headaches, than in people who do not have Parkinson's Disease, 70% of whom had headaches. The prevalence of headaches being significantly lower in people with Parkinon's Disease is unexplained by the researchers.
Fewer people with Parkinson's Disease (74%) had headaches throughout life in contrast to the 94% of people who had headaches throughout life who did not have Parkinson's Disease. Considering only people who had headaches during the previous year, people with Parkinson's Disease had a higher association with migraine rather than tension headaches compared to people who did not have Parkinson's Disease. The headache side in people with Parkinson's Disease was also on the same side as the side of Parkinson's Disease onset in 84 % of people. In order to refer to this article on its own click here.
6th November 2013 - New research
THE CAUSES OF FALLS IN PARKINSON'S DISEASE
Neurologia i neurochirurgia polska  47 (5) : 423-430 (Rudzinska M, Bukowczan S, Stozek J, Zajdel K, Mirek E, Chwala W, Wójcik-Pedziwiatr M, Banaszkiewicz K, Szczudlik A.) Complete abstract
Neurologia i neurochirurgia polska  47 (5) : 431-437 (Rudzinska M, Bukowczan S, Stozek J, Zajdel K, Mirek E, Chwala W, Wójcik-Pedziwiatr M, Banaszkiewicz K, Szczudlik A.) Complete abstract
People with Parkinson's Disease suffer falls more frequently than most other people. Over the year falls occurred in 54% of people with Parkinson's Disease. Around 20% of people with Parkinson's Disease fell frequently. This occurred more commonly with age.
Analysis of causes of falls revealed that sudden falls were the most common (31%), followed by episodes of freezing and festination (19%), neurological and sensory disturbances (mostly vertigo) (12%), environmental factors (12%), postural instability (11%), orthostatic hypotension (4%), and severe dyskinesia (3.6%). In people with Parkinson's Disease, factors due to themselves were dominant, whereas in the control group external factors were responsible for falls with the same frequency. Every third fall intensified the fear of walking. Over a third (34%) of falls caused injuries. Among them bruises of body parts other than the head were most frequent. In order to refer to this article on its own click here.
31st October 2013 - News release
SENSORY PEN FOR DETECTING PARKINSON'S DISEASE
A means of diagnosing Parkinson’s Disease is being developed by MANUS Neurodynamica using sensory pen technology. It is called the DiPAR project. The system, combining sensor and computing technology, requires the patient to perform a set of writing tasks, drawing activities or a combination of both. The system records all movements of the pen as well as other parameters such as drawing pressure, plus acceleration and deceleration of movement, to identify patterns that are indicative of specific kinds of neuromotor disorder. The sensory pen can be used by non-specialists with minimal training so that large numbers of people would be able to be screened.
The system’s software records key features regarding the movement of the pen, relating it to the motion of the limb, particularly the role of the hand and fingers in coordinating overall pen motion. The recordings enable the operator to assess akinesia, bradykinesia, tremor, rigidity and other signs of motor deterioration that cannot be easily detected by other means. The software takes inputs from a variety of sensors in the pen and converts them, using proprietary algorithms, into outcome percentages that represent the likelihood of the presence of Parkinson's Disease or other neuromotor disorders. The method can be viewed in this brief video video of sensory pen technology. In order to refer to this article on its own click here.
13th October 2013 - New research
THE LONG TERM EFFECT OF DBS ON PARKINSON'S DISEASE
Journal of the Formosan Medical Association  Oct 5
[Epub ahead of print] (J.L.Jiang,
S.Y.Chen, T.C.Hsieh, C.W.Lee, S.H.Lin, S.T.Tsai)
The aim of this study was to assess the improvements that can be expected after 1 year and after 5 years. Patients with Parkinson's Disease were assessed after 1 year and 5 years according to the Unified Parkinson's disease rating scale (UPDRS) parts I, II, III, and IV scores, the Hoehn and Yahr stage, and Schwab and England activities of daily living (SEADL) scores in the conditions of off-medication/on-stimulation and off-medication/off-stimulation. Further analysis included the changes in the L-dopa equivalent daily dose.
After 1 year significant improvements were seen in the UPDRS parts I, II, III, and IV and the Schwab and England scale. Five years after STN-DBS had been initiated improvements in UPDRS scores were observed only for parts II, III, and IV. In the off-medication/off-stimulation condition no significant improvement was observed. However, after 5 years there were significant deteriorations when compared to the improvements seen after 1 year in the scores for the UPDRS parts I, II, III and the Schwab and England scale. Therefore, after the improvement experienced after 1 year the long term trend is downwards. For a printable version of this article click here. In order to refer to this article on its own click here.
7th October 2013 - New research
DUAL LAYER L-DOPA CLINICAL TRIAL RESULTS
Parkinsonism Related Disorders  Sep 5 [Epub ahead of print] (R.Pahwa,
K.E.Lyons, R.A.Hauser, S.Fahn, J.Jankovic, E.Pourcher, A.Hsu, M.O'Connell,
All three dosages improved Parkinson's Disease, with the 145mg dosage, then the 245mg dosage giving better results. The most commonly reported adverse events with IPX066 included nausea, dizziness, and headache. No unexpected drug-related serious adverse events were reported. For a printable version of this article click here. In order to refer to this article on its own click here.
3rd October 2013 - New research
DEPRESSION TREBLES THE RISK OF PARKINSON'S DISEASE
Neurology  Oct 2 [Epub ahead of print] (Cheng-Che Shen, Shih-Jen
Tsai, Chin-Lin Perng, Benjamin Ing-Tiau Kuo, Albert C.Yang)
Parkinson's Disease is primarily due to the insufficient formation of dopamine in the brain, in the dopaminergic neurons. Besides affecting muscle function and therefore the characteristic muscular symptoms of Parkinson's Disease such as as rigidity and tremor, dopamine insuffiency also affects the emotions.
This is why dopamine insufficiency can also lead to depression. However, even biochemically, dopamine is not the only factor involved in depression, which is why depresssion and Parkinson's Disease do not always coincide. Therefore, depression, even when severe, does not inevitably lead to Parkinson's Disease and why it is possible to have Parkinson's Disease without also having depression. For a printable version of this article click here. In order to refer to this article on its own click here.
3rd October 2013- New book
UNDERSTANDING PARKINSON'S DISEASE : AN INTRODUCTION FOR PATIENTS AND CAREGIVERS
Publisher's description : Understanding Parkinson’s Disease offers patients and their caregivers the kind of cutting-edge information that will allow them to successfully confront this debilitating disease on a number of fronts. Patients will also be uniquely exposed to alternative approaches to managing the symptoms of the disease, including allopathic, osteopathic, and naturopathic approaches. The reader will be introduced to essential information on the risk factors associated with Parkinson’s, the signs and symptoms, the different stages of the disease, the various treatments, as well as how the disease develops. Anyone looking for an introduction will find the information they need in this accessible resource. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
29th September 2013 - New research
HOUSEHOLD PESTICIDES INCREASE THE RISK OF PARKINSON'S DISEASE
International Journal of Epidemiology  Sep 20 [Epub ahead of print]
(S.Narayan, Z.Liew, K.Paul, P.C.Lee, J.S.Sinsheimer, J.M.Bronstein, B.Ritz)
Consequently, researchers investigated whether long term use of household pesticides, especially those containing organophosphorus chemicals, increases the risk of developing or worsening Parkinson's Disease. Frequent use of any household pesticide increased the risk of developing Parkinson's Disease by 47%. Frequent use of products containing organophosphorus chemicals increased the risk of Parkinson's Disease by 71%. Frequent organothiophosphate use almost doubled the risk of Parkinson's Disease. The evidence shows that household use of organophosphorus pesticides is clearly associated with an increased risk of Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
26th September 2013 - New research
THE WORLD'S LOWEST INCIDENCE OF PARKINSON'S DISEASE
Journal of Neural Transmission  Sep 22 [Epub ahead of print]
(C.L.Ma, L.Su, J.J.Xie, J.X.Long, P.Wu, L.Gu)
The world's lowest incidence of Parkinson's Disease has been found to be in China. Incidence is the rate at which Parkinson's Disease is being newly diagnosed. The incidence of Parkinson's Disease in China, at only 2 people per 100,000 is remarkably low. In constrast, the incidence rate in the U.S.A. is about ten times that number. The prevalence of Parkinson's Disease in China is remarkably high, with 797 per 100,000 being one of the highest rates in the world. The ratio of men to women with Parkinson's Disease is, at 1.29 men for every woman, more typical.
With very high prevalence (those people that have Parkinson's Disease now) and very low incidence (those people that are being diagnosed) means that the number of people in China with Parkinson's Disease must be dropping rapidly, and at a greater rate than anywhere else in the world. The researchers provide no reasons for this. In China, instead of standard Parkinson's Disease drugs, people tend to use more Chinese herbal remedies, a number of which are known to have effect in Parkinson's Disease. For more information go to Herbal Medicines for Parkinson's Disease For a printable version of this article click here. In order to refer to this article on its own click here.
The former Chinese leader Chairman Mao is known to have had Parkinson's Disease. However, it is never disclosed in China that Chairman Mao, who is given almost God like status in China, ever actually had Parkinson's Disease.
22nd September 2013 - New research
THE EFFECT OF TEN YEARS WITH PARKINSON'S DISEASE
Parkinsonism Related Disorders  18 supplement, 3 : S10-S14 28 (3) :
S.S.Wu, P.Schmidt, I.A.Malaty, Y.F.Dai, J.M.Miyasaki, M.S.Okun)
They had an average of two additional medical disorders with arthritis (49%) and heart problems (32%) being the most common. Most of them (87%) took at least 2 medications, with L-dopa (96%), dopamine agonists (45%) and antidepressants (37%) being the most common. Most of them were not currently utilizing physical, occupational or speech therapy, but two-thirds of them reported engaging in physical activity. Deep brain stimulation was documented in 22%. Overall the mean health-related quality of life and caregiver burden was impaired in all domains. For a printable version of this article click here. In order to refer to this article on its own click here.
21st September 2013 - New research
COFFEE INTAKE AND THE RISK OF DYSKINESIA
Movement Disorders  28 (3) : 380-383 (A.M.Wills, S.Eberly, M.Tennis,
A.E.Lang, S.Messing, D.Togasaki, C.M.Tanner, C.Kamp, J.F.Chen, D.Oakes,
Researchers examined the association between the intake of caffeine and the time taken to develop dyskinesia. Those people who consumed 12 ounces of coffee per day, which is about two cups, reduced their likelihood of developing dyskinesia to 61%. Those people who consumed 4 to 12 ounces of coffee per day, which is less than two cups per day, reduced their likelihood of developing dyskinesia to 73%. The authors suggest tha these results support the possibility that caffeine may reduce the likelihood of developing dyskinesia. For a printable version of this article click here. In order to refer to this article on its own click here.
16th September 2013 - News report
BILLY CONNOLLY DIAGNOSED WITH PARKINSON'S DISEASE
The 70 year old Scottish comedian Billy Connolly has been diagnosed with Parkinson's Disease but has vowed to continue with his stage and screen career despite also having prostate cancer. Besides being known for stand up comedy on television and in large arenas he has appeared as a comedian and as a serious actor in films such as The Last Samurai, The Hobbit, Indecent Proposal, Muppet Treasure Island, and Gulliver's Travels. For more information go to Billy Connolly. Connolly’s spokesman revealed that "Billy has been assured by experts that the findings will in no way inhibit or affect his ability to work, and he will start filming a TV series as well as undertaking an extensive theatrical tour." For more details go to Daily Mail.
9th September 2013 - New review
FUTURE FORMS OF L-DOPA FOR PARKINSON'S DISEASE
The forms of L-dopa presently being developed are likely to completely change the way that L-dopa is used. They include Inhaled L-dopa, Dual layer L-doopa, Subcutaneous L-dopa, L-dopa prodrug, Melevodopa and AcuForm.
Mucuna Pruriens has been a source of L-dopa since ancient times. As a drug, L-dopa started out as a treatment on its own. Sinemet and Madopar combined L-Dopa with a decarboxylase inhibitor in order to reduce the loss of L-dopa before it was used. In order to spread out the effect of L-dopa, controlled release versions of Sinemet andd Madopar were then produced, Stalevo added Entacapone to that combination. Entacapone is a COMT inhibitor, which is able to slow down the degradation of L-dopa. An improved version of Stalevo called ODM-101 is already being developed. Parcopa is an orally disintegrating combination of L-dopa and carbidopa, which is the same combination as Sinemet. Duodopa is a combination of L-dopa and carbidopa in the form of a gel, which is administered throughout the day using a portable pump directly into the small intestine through a surgically placed tube.
New forms of L-dopa presently being developed for the treatment of Parkinson's Disease are :
6th September 2013 - New research
SAFINAMIDE CLINICAL TRIAL RESULTS
European Journal of Neurology  September 11 [Epub ahead of print]
(A.H.Schapira, F.Stocchi, R.Borgohain, M.Onofrj, M.Bhatt, P.Lorenzana,
V.Lucini, R.Giuliani, R.Anand)
In a one year clinical trial people with Parkinson's Disease received 100mg or 200mg Safinamide daily. They were assessed according to how long it was before they had to increase their dopamine agonist dose or add another Parkinson's Disease treatment. People receiving 100 mg/day safinamide experienced a significantly lower rate of intervention compared with placebo, of 25% instead of 51% and a small delay before the need to increase other Parkinson's Disease treatments of 9 days.
In a previous study of once daily dosages of 50mg to 100mg Safinamide improved Parkinson's Disease symptoms after six months and reduced "off" time when added on to the use of existing Parkinson's Disease treatments. However, the reduction in "off" time in comparison to the use of a placebo was minimal. The increase in "on" time beyond that of a placebo was only 40 minutes for 50mg safinamide, and 50 minutes for 100mg safinamide. For more information go to thee Complete abstract. For a printable version of this articlee click here. In order to refer to this article on its own click here.
4th September 2013- New book
DEMENTIA WITH LEWY BODIES AND PARKINSON'S DISEASE DEMENTIA
Publisher's description : In Dementia with Lewy Bodies and Parkinson's Disease Dementia, Dr. J. Eric Ahlskog draws on 30 years of clinical and research work at Mayo Clinic to arm patients and families with crucial information that will enable them to work in tandem with their doctors. Dr. Ahlskog clearly explains all aspects of these disorders, their causes, symptoms, most effective drug treatments, proper doses, and which medications to avoid. He also discusses the complications that can arise in treating these conditions, given the variety of available medications and their possible side effects and interactions. Dr. Ahlskog shows that optimal medical treatment can markedly improve the quality of life for both patients and family. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
1st September 2013 - New research
NEUPRO CLINICAL TRIAL RESULTS
PLoS One  8 (7) : e69738 (C.Q.Zhou, S.S.Li, Z.M.Chen, F.Q.Li, P.Lei,
26th August 2013 - New research
NAVAJO HAVE ONE OF THE HIGHEST PREVALENCES OF PARKINSON'S DISEASE
Journal of Parkinson's Disease ]
3 (2) : 193-198 (P.H.Gordon, H.Zhao, D.Bartley, L.J.Sims, M.G.Begay, S.
Pirio Richardson, J.Lewis, A.S.Rowland)
These figures are higher than for any U.S. state with Nebraska having the highest prevalence at 329 per 100,000. Amongst Navajo men it is even higher at 438 per 100,000. The Navajo are concentrated in Arizona and New Mexico in the USA. For more information go to Navajo. Native Americans, including American Indian and Alaska Native peoples as a whole have an even higher prevalence rate of 355 per 100,000. It is not known why the prevalence is so high amongst Native Americans. For more information concerning prevalence go to Prevalence of Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
24th Augustt20133- News report
LINDA RONSTADT DIAGNOSED WITH PARKINSON'S DISEASE
American singer Linda Ronstadt has been diagnosed with Parkinson's Disease and
consequently can no longer sing. She won 11 Grammy Awards and has gold, platinum
and multiplatinum albums. sing. For more information go to
Linda Ronstadt. Linda Ronstadt, who
is now 67, told AARP today that she was daignosed with Parkinson's Disease 8
months ago and that she began to show symptoms 8 years ago. Linda Ronstadt now
walks with the aid of poles when on uneven ground and uses a wheelchair when she
travels. However, her soon to be published autobiography makes no mention of her
having Parkinson's Disease. For more information
23rd August 2013- New book
YOGA AND PARKINSON'S DISEASE
Peggy Van Hulsteyn
Publisher's description : Yoga and Parkinson's Disease is a practical guide to using yoga to manage stress, improve mental alertness, increase flexibility, correct posture and improve the quality-of-life of readers with Parkinson's. It follows the author's own experience and research studies in the subject that have shown a correlation between yoga practice and better health and outcomes after a Parkinson's Disease diagnosis. The book is a deeply soothing form of moving meditation and physical activity that is a safe way to rebuild strength, stamina, and flexibility. It shows how yoga ameliorates difficulties that accompany Parkinson's, including mobility, range of motion, and balance. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
18th August 2013 - New research
THE EFFECT OF GAMMA KNIFE THALAMOTOMY ON TREMOR
Journal of Neurosurgery  118 (4) : 713-718 (A.Kooshkabadi, L.D.Lunsford,
D.Tonetti, J.C.Flickinger, D.Kondziolka)
Knife radiosurgical thalamotomy is a technique in which a thalamotomy is
performed with beams of radiation rather than a surgical incision or use of
electrodes. The surgeon uses a Gamma Knife device to focus high-energy gamma
rays precisely on an area in the brain that causes tremor. These rays result
in the death of the brain cells that generate tremor. The procedure takes
approximately one hour and the benefit may not be apparent until three to
six weeks afterwards. For more information go
Gamma knife srugery.
13th August 2013 - New research
BIOMARKERS FAIL TO DIAGNOSE PARKINSON'S DISEASEE
BMC Neurology  Apr 12
[Epub ahead of print] (D.J.McGhee, P.L.Royle, P.A.Thompson,
D.E.Wright, J.P.Zajicek, C.E.Counsell)
A systematic review was undertaken to determine which biomarkers for disease progression in Parkinson's Disease exist. 183 studies were included. The sensitivity of the tests was an average of 71%, which is insufficient for Parkinson's Disease diagnosis. However, the range in sensitivity was between 51% and 86% showing that some of the methods were closer to having a practical use but were still less accurate than other methods of diagnosing Parkinson's Disease that are available. The authors found insufficient evidence to recommend the use of any biomarker for assessing disease progression in Parkinson's Disease clinical trials. They believe that this may simply reflect the poor quality of research in this area. They therefore present a provisional 'roadmap' for conducting future disease progression biomarker studies and recommend new quality criteria by which future studies may be judged. For a printable version of this article click here. In order to refer to this article on its own click here.
8th August 2013 - New research
DIABETIC DRUG TO TREAT PARKINSON'S DISEASE
Journal of Clinical Investigation  123 (6) : 2730-2736 (I.Aviles-Olmos,
J.Dickson, Z.Kefalopoulou, A. Djamshidian, P.Ell, T.Soderlund, P.Whitton,
R.Wyse, T.Isaacs, A.Lees, P.Limousin, T.Foltynie)
People with moderate Parkinson's Disease received subcutaneous injections of Exenatide for a year. Their Parkinson's Disease was compared after overnight withdrawal of conventional Parkinson's Disease medication using the Unified Parkinson's Disease Rating Scale (UPDRS). Exenatide was well tolerated but weight loss was common. There were clinically relevant improvements in Parkinson's Disease motor and cognitive measures. Exenatide treated patients had a mean improvement after one year on the UPDRS of 2.7 compared with a mean decline of 2.2 points in controls. The authors do not make suggestions as to how the diabetes drug has effect in Parkinson's Disease. For a printable version of this articlee click here. In order to refer to this article on its own click here.
7th August 2013 - News release
BASEBALL STAR DIAGNOSED WITH PARKINSON'S DISEASE
Dave Parker, a two time winner of the baseball World Series has been diagnosed with Parkinson's Disease. Dave Parker is a retired American baseball player. He began his career in the Major League in 1973 with the Pittsburgh Pirates, where he spent ten years. He went on to play with Cincinnati Reds, Oakland Athletics, Milwaukee Brewers, California Angels, and Toronto Blue Jays. He won the World Series twice, in 1979 and 1989. He retired from baseball in 1991. Now aged 62, he was first diagnosed with Parkinson's Disease early in 2012 but kept it quiet until now except for informing some close friends. For the time being he is not taking any medication and is instead relying on natural remedies. For more information concerning him go to Dave Parker
4th August 2013 - New research
CLINICAL TRIAL OF AFQ056 FOR DYSKINESIA
Movement Disorders  July 11 [Epub ahead of print] (Stocchi F, Rascol O,
Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H,
Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C.)
Patients taking 200mg AFQ056 daily demonstrated significant improvements on the modified Abnormal Involuntary Movements Scale. There was a dose-response relationship, with 200 mg daily demonstrating thee greatest effect. However, no significant changes were observed on the 26-item Parkinson's Disease Dyskinesia Scale or the Patient's / Clinician's Global Impression of Change. Unified Parkinson's Disease Rating Scale part III scores were not significantly changed, indicating no worsening of motor symptoms. The most common adverse events were dizziness, hallucination, fatigue, nasopharyngitis, diarrhea, and insomnia. These results can guide the slection of doses for future clinical trials. For a printable version of this articlee click here. In order to refer to this article on its ownn click here.
29th July 2013 - New research
PRAMIPEXOLE : EXTENDED RELEASE v IMMEDIATE RELEASE
Drug Research  Jul 24 [Epub ahead of print] (M.Takanashi, Y.Shimo,
T.Hatano, G.Oyama, N.Hattori)
This study aimed to evaluate the efficacy and safety of an extended-release tablet formulation of pramipexole (PPX-ER) given once daily when switched from an immediate-release tablet formulation (PPX-IR) given 3 times daily. The extended release version evens out the effect of Pramipexole. Parkinson's Disease symptom scores were reduced after 4 weeks and after 8 weeks. There was no change in the nocturnal and early morning symptoms (NEMS) score, or the Parkinson's Disease Sleep Scale (PDSS-2). Nearly two thirds of patients and caregivers preferred the extended release version. For a printable version of this articlee click here. In order to refer to this article on its own click here.
26th July 2013 - New research
COFFEE REDUCES THE RISK OF PARKINSON'S DISEASE
Geriatrics and Gerontology International  Jul 23 [Epub ahead of print]
When tea and caffeine were included in the assessment the risk of Parkinson's Disease reduced in relation to the intake. The risk of Parkinson's Disease was reduced by 26% for every two cups of tea consumed and by 17% for every 200mg of caffeine taken. The association of coffee and tea consumption with the risk of Parkinson's Disease was stronger for men than it was for women. The association of caffeine consumption with the risk of Parkinson's Disease was stronger in postmenopausal women when they had ever used hormones. These associations were weaker in the USA than they were in Europe and Asia.
Caffeine and theophylline, which is found in tea, are a type of drug called adenosine antagonists. Adenosine antagonists include drugs presently being developed for the treatment of Parkinson's Disease including : Preladenant, Tozadenant, and Istradefylline. For a printable version of this article click here. In order to refer to this article on its own click here.
23rd July 2013 - New book
MAKING THE CONNECTION BETWEEN BRAIN AND BEHAVIOR
Publisher's description : Although many patients and families are aware of the physical challenges that accompany Parkinson's disease, few are prepared to deal with the common behavioral issues that impact their quality of life. Behavior problems in PD are not always catastrophic, but they are common. It is estimated that 65-90% of PD patients experience some level of depression, anxiety, dementia, hallucinations, paranoid delusions, sleep disorders, and other behavioral disorders that affect everyone involved. The self-contained chapters will help readers understand, address, and cope with common behavioral issues, as well as provide guidance on ways to communicate with the healthcare team. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
21st July 2013 - New research
THE PREVALENCE OF IMPULSE DISORDERS IN PARKINSON'S DISEASE
Journal of Clinical Psychopharmacology  July 12 [Epub ahead of print]
(M.Poletti, C.Logi, C.Lucetti, P.Del Dotto, F.Baldacci, A.Vergallo, M.Ulivi,
S.Del Sarto, G.Rossi, R.Ceravolo, U.Bonuccelli)
Impulse control disorders were significantly associated with dopamine agonists, making Impulse control disorders 5.5 times more likely. Impulse control disorders frequency was greater but similar for the dopamine agonists pramipexole and ropinirole. The use of L-dopa made Impulse control disorders 2.4 times more likely. So although dopamine agonists more commonly cause them, L-dopa is still a common cause. Other factors associated with Impulse control disorders being more likely were being male and being younger age. So although dopamine agonists are the most common cause there can be a combination of factors that are responsible. For a printable version of this article click here. In order to refer to this article on its own click here.
17th July 2013 - New research
ALCOHOL AND THE RISK OF PARKINSON'S DISEASE
PLoS One  8 (6) : e66452 (R.Liu, X.Guo, Y.Park, J.Wang, X.Huang,
A.Hollenbeck, A.Blair, H.Chen)
Compared with non-beer drinkers, beer drinkers were less likely to develop Parkinson's Disease, whether they had less than 1, 1 to 2, or 2 drinks per day. For liquor (spirit) drinkers the likelihood of developing Parkinson's Disease appeared to gradually increase with the number of drinks they consumed per day, but with less than one drink per day making no difference. The results for wine consumption were less clear. However, a drink or two of wine per day made no difference to the risk of Parkinson's Disease. So beer drinking appears to be associated with a reduced likelihood of developing Parkinson's Disease, but liquor (spirit) drinking appears to be associated with an increased likelihood of developing Parkinson's Disease. For a printable version of this articlee click here. In order to refer to this article on its own click here.
14th July 2013 - New research
L-DOPA INCREASES THE RISK OF NEUROPATHY
Movement Disorders  Jul 8 [Epub ahead of print] (R.Ceravolo, G.Cossu,
M.B.di Poggio, L.Santoro, P.Barone, M.Zibetti, D.Frosini, V.Nicoletti,
F.Manganelli, R.Iodice, M.Picillo, A.Merola, L.Lopiano, A.Paribello, D.Manca,
M.Melis, R.Marchese, P.Borelli, A.Mereu, P.Contu, G.Abbruzzese, U.Bonuccelli)
Motor nerve damage leads to symptoms such as muscle weakness, cramps, spasms, a loss of balance and coordination. People may find it difficult to walk, feel like they have heavy legs, stumble, or tire easily. Damage to arm nerves may make it difficult to do routine tasks like carry bags, open jars, or turn door knobs. Sensory nerve damage can cause tingling, numbness, pinching and pain. Autonomic nerve damage can lead to abnormal blood pressure and heart rate, reduced ability to perspire, constipation, bladder dysfunction, diarrhea, incontinence, sexual dysfunction, and thinning of the skin. For more information go to Neuropathy.
Those people taking L-dopa for more than 3 years were most affected with nearly 20% of them being diagnosed with neuropathy. Only 7% of those people taking L-dopa for less than three years were diagnosed with neuropathy. The risk of neuropathy was not influenced by : Parkinson's Disease duration, severity of Parkinson's Disease or gender. The risk of neuropathy increased by approximately 8% for each year of age. The L-dopa dosages were higher in those affected. So L-dopa dosage and duration and age were the main risk factors for neuropathy. For a printable version of this article click here. In order to refer to this article on its own click here.
11th July 2013 - New research
THE EFFECT OF PHYSIOTHERAPY ON PARKINSON'S DISEASE
Neurochirurgia Polska  47 (3) : 256-262 (J.Cholewa, M.Boczarska-Jedynak,
The main emphasis was placed on the ability to cope with daily activities. A significant difference in scores on the given scales was observed before and after the 12-week assessment period. Parkinson's Disease symptom score (UPDRS part I) improved by 17%, part II improved by 22%, part III improved by 19%, and PDQ-39 score improved by 17%. Mean score of the Schwab and England scale improved by 9%, indicating an improved quality of life. The rehabilitation programme clearly improved the severity of motor symptoms in people with Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
7th July 20133
THE MODIFIED RANKIN SCALE FOR ASSESSING PARKINSON'S DISEASE
Journal of Clinical Neuroscience  Jun 26 [Epub ahead of print] (T.Simuni, S.T.Luo, K.L.Chou, H.Fernandez, B.He, S.Parashos)) Complete abstract
An exploratory analysis was conducted in to the use of the modified Rankin Scale (mRS) as a global measure of disability in early Parkinson's Disease. For more information go to the Modified Rankin Scale The mRS assesses the level of disability caused by neurological disorders. It is scored 0-6 with lower scores reflecting less disability.
1 - No significant disability : Able to carry out all usual activities,
despite some symptoms.
The association of the Modified Rankin Scale was compared with Parkinson's Disease related assessments : the Unified Parkinson Disease Rating Scale (UPDRS), cognitive function characterized by the Symbol Digit Modalities - verbal, Scales for Outcomes in Parkinson's disease - cognition (SCOPA-COG), quality of life (Parkinson's disease questionnaire (PDQ-39), EuroQOL, Beck Depression Inventory II (BDI), and Total Functional Capacity (TFC). All of the measures except SCOPA-COG had a significant association with the modified Rankin Scale thereby demonstrating its significance to Parkinson's Disease. For a printable version of this articlee click here. In order to refer to this article on its own click here.
4th July 2013 - New research
THE EFFECT OF DEEP BRAIN STIMULATION (DBS) ON PARKINSON'S DISEASE
Ideggyogy Sz.  66 (3-4) : 115-120 (G.Tamás, A.Takáts, P.Radics, I.Rózsa, E.Csibri, G.Rudas, P.Golopencza, L.Entz, D.Fabó, L.Eross) Complete abstract
Researchers assessed the effect of Deep Brain Stimulation (DBS) on the different types of symptoms experienced in Parkinson's Disease. Deep Brain Stimulation (DBS)) involves the use of electrodes that are implanted into the brain and connected to a small electrical device called a pulse generator that can be externally programmed. DBS requires careful programming of the stimulator device. For more information go to Deep brain stimulation
The major Parkinson's Disease symptom score
(the Unified Parkinson's Disease Rating Scale) decreased by 70%. Patient
condition improved according to the Hoehn-Yahr scale, approximately by two
stages. Twelve hours
after the withdrawal of Parkinson's Disease drugs execution of daily activity
improved by 57% and motor functions developed by 79%. Duration of dyskinesias
decreased by 62%. Duration of akinesia diminished by 87%. Quality of life rose
by 41%. Neuropsychological tests detected improvement in verbal memory. The
dosage of Parkinson's Disease drugs could be reduced by 63% after the operation
had been completed.
24th June 2013 - New research
RASAGILINE'S EFFECT ON TREMOR IN PARKINSON'S DISEASE
The International Journal of Neuroscience  Jun 17 [Epub ahead of print] (M.F.Lew) Complete abstract
Researchers reviewed the effects on tremor in Parkinson's Disease of 1mg daily oral rasagiline, on its own and with other treatments. Tremor is a common symptom of Parkinson's Disease, but it is less responsive to dopaminergic therapy than are the symptoms of bradykinesia and rigidity. Rasagiline is a MAO inhibitor that is marketed as Azilect. For more information go to Azilect.
Of 22 identified publications, 2 large placebo-controlled trials of rasagiline monotherapy (TEMPO and ADAGIO) and 2 large placebo controlled trials of rasagiline with L-dopa (PRESTO and LARGO) specifically evaluated the effect of rasagiline on tremor using the Unified Parkinson's Disease Rating Scale (UPDRS). Analysis of these studies showed rasagiline on its own significantly improved tremor in early Parkinsons' Disease independently of disease duration.
In people taking L-dopa who had motor fluctuations who were already receiving optimal dopaminergic treatment, the addition of rasagiline significantly improved their tremor. Significant improvement was evident as early as ten weeks from the initiation of the use of rasagiline. Tremor symptoms also improved in people with severe tremor when rasagiline was added to their existing Parkinson's Disease treatments. The researchers contend that the data suggest that rasagiline used on its own or alongside other treatments is effective for reducing tremor severity in people with Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its ownn click here.
19th June 2013 - New research
SWEETENER FOR TREATING PARKINSON'S DISEASE
Journal of Biological Chemistry  288 (24) : 17579-17588 (R.Shaltiel-Karyo, M.Frenkel-Pinter, E.Rockenstein, C.Patrick, M.Levy-Sakin, A.Schiller, N.Egoz-Matia, E.Masliah, D.Segal, E.Gazit) Complete abstract
The sweetener, mannitol, has been proposed as a potential means of treating Parkinson's Disease because of the dual mechanisms it has in the brain. Mannitol, which is used in medicine, is derived from mannose, which is a sugar. For more information go to Mannitol.
Researchers assessed the ability of mannitol to (1) interfere with the aggregation of alpha-synuclein, and (2) its ability to disrupt the blood-brain barrier. Alpha-synuclein can accumulate in the brains of people with Parkinson's Disease and other medical disorders but can also be absent in Parkinson's Disease. It therefore appears that Parkinson's Disease can cause alpha-synuclein rather than alpha-synuclein being the cause of Parkinson's Disease as is often claimed. The blood brain barrier restricts access to the brain to certain substances. They demonstrated the effect of mannitol on alpha-synuclein by various means, and a decrease in alpha-synuclein accumulation.
The researchersstherefore suggest mannitol as a basis for a dual mechanism therapeutic agent for the treatment of Parkinson's Disease. However, the research was only carried out on mice and flies, who did not have Parkinson's Disease and who were not rid of its symptoms. For a printable version of this article click here. In order to refer to this article on its ownn click here.
13th June 2013 - New research
THE EFFECT OF PRAMIPEXOLE ON PARKINSON'S DISEASE
Lancet Neurology  May 30 [Epub ahead of print] (A.H.Schapira, M.P.McDermott, P.Barone, C.L.Comella, S.Albrecht, H.H.Hsu, D.H.Massey, Y.Mizuno, W.Poewe, O.Rascol, K.Marek) Complete abstract
The Pramipexole On Underlying Disease (PROUD) study was designed to identify whether or not early versus delayed pramipexole initiation has clinical benefits in people with Parkinson's Disease. Pramipexole, which is sold as Mirapex, Mirapexin and Sifrol, is aa dopamine agonist used for treating early-stage Parkinson's Disease. For more information go to Mirapex.
People taking pramipexole were given 1.5mg pramipexole per day. The average difference in Parkinson's Disease symptom scores (the UPDRS) showed no significant difference between early and delayed pramipexole. Fifteen months of use showed no benefit when compared to the use of pramipexole being delayed for 6 to 9 months. Over 80% of people who took pramipexole reported adverse events, with 81% of those given early pramipexole and 84% of those given delayed pramipexole. The most frequent adverse event was nausea. Serious adverse events were reported by 10% of people in the early pramipexole group and 8% in the delayed pramipexole group. The authors conclude that the results do not support the hypothesis that pramipexole has disease-modifying effects. For a printable version of this article click here. In order to refer to this article on its own click here.
5th June 2013 - New research
BREATH TEST TO DIAGNOSE PARKINSON'S DISEASE
Nanomedicine  8 (1) : 43-56 (U.Tisch, I.Schlesinger, R.Ionescu, M.Nassar, N.Axelrod, D.Robertman, Y. Tessler, F.Azar, A.Marmur, J.Aharon-Peretz, H.Haick) Complete abstract
A method of diagnosing Parkinson's Disease has been developed that uses breath
testing. It can identify Parkinson's Disease and Alzheimer's Disease. Alveolar
breath was collected from people with Parkinson's Disease or Alzheimer's Disease
or who had neither. Their breath was analyzed using sensors (organically
functionalized carbon nanotubes and gold nanoparticles). Statistically
significant differences were compared between the different groups, which was
supported by chemical analysis of the breath samples using gas chromatography
combined with mass spectrometry.
|GO TO MAY 2013|
ARCHIVESJuly August September October November December March April May June July August September October November December March April May June July August September October November December